Search

Search Constraints

You searched for: Author/Creator Hartung, Hans-Peter

Search Results

1. 031  Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years. Issue 6 (27th May 2022)

2. 044 Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study). Issue 6 (24th May 2018)

4. 17. Benefit-Risk Profile of Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): The PATH study. Issue 3 (March 2020)

5. 18. Secondary endpoints (PATH extension study): Long-term outcomes of subcutaneous immunoglobulin IgPro20 in CIDP maintenance treatment. Issue 3 (March 2020)

6. 19. Pharmacokinetic modelling and simulation of flexible dosing regimens of subcutaneous immunoglobulin (IgPro20) in CIDP patients. Issue 3 (March 2020)

8. 21. Exposure-response of serum IgG levels and INCAT scores in CIDP patients receiving subcutaneous immunoglobulin (IgPro20). Issue 3 (March 2020)

10. A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. (June 2015)